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PURPOSE:  Every year, thousands of Americans pursue prenatal diagnosis of fetal aneuploidy 
though chorionic villus sampling (CVS) or amniocentesis.  Because these procedures are 
invasive and carry an inherent risk for pregnancy loss, they are selectively offered to women who 
have an increased risk to have a child with a chromosome condition, such as aneuploidy.  I n 
order to identify pregnancies at an increased risk, several non-invasive screening methods have 
been developed.  Although quite useful, these screening methods have limited accuracy and can 
only be completed during specific gestational age windows.  Recent discovery of cell free fetal 
DNA in maternal circulation has created new and exciting possibilities for prenatal screening and 
non-invasive prenatal diagnosis.  This research study explores shotgun next-generation 
sequencing of fetal DNA in maternal plasma as a method for non-invasive identification of fetal 
aneuploidy. 
METHODS:  We carried out shotgun next-generation sequencing on samples of maternal 
plasma DNA obtained in the first trimester of pregnancies with confirmed aneuploidy and 
control pregnancies.  Three Trisomy 21 samples were compared to four control samples in order 
to identify any differences in the amount of chromosomal material.  
RESULTS:  We identified a statistically significant increase in chromosome 21 material in the 
cases of Trisomy 21 as compared to the control cases. 
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IMPLICATIONS:  This research demonstrates that shotgun next-generation sequencing of 
maternal plasma DNA can successfully identify Trisomy 21, showing that it is possible to detect 
fetal aneuploidy using this noninvasive method.  This technology could potentially be used as a 
method of noninvasive screening for fetal aneuploidy, which is likely to have improved accuracy 
over other screening methods.  Development of a screening test with greater sensitivity and 
specificity could have significant public health implications.  This would not only provide more 
accurate identification of pregnancies at an increased risk for aneuploidy, but it would also 
reduce the number of false positives.  This in turn would reduce the number of pregnancies that 
are unnecessarily classified as “high risk”, preventing avoidable parental anxiety and reducing 
the number of pregnancies that are put at unnecessary risk of invasive prenatal diagnostic 
procedures. 
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1.0  INTRODUCTION 
Chromosome conditions, such as aneuploidy, occur in approximately 20-50% of pregnancies [1-
3].  I t has been understood that the chance a woman will have a pregnancy with aneuploidy 
increases with her age [4-7].  Because of this, women are routinely offered screening tests that 
can help to identify fetuses at an increased risk for having a chromosome condition [8].  One 
such screening test is the First Trimester Screen, which combines blood work and ultrasound to 
adjust a women’s age-related risk to a risk that is more personalized to her pregnancy [8].  The 
results of a “positive” screen result often lead to consideration of prenatal diagnosis options, such 
as Chorionic Villus Sampling or Amniocentesis.  T hese procedures are invasive and carry an 
inherent risk for miscarriage.  Although minimally invasive and low in cost, the First Trimester 
Screen has a sensitivity of approximately 85% and has a high false positive rate [8-10].  This 
may lead to unnecessary prenatal diagnostic procedures which, sequentially, would place these 
pregnancies at unnecessary risk.  Recent efforts to improve methods for non-invasive aneuploidy 
detection have focused on the analysis of cell-free fetal DNA, which is detectable at low levels in 
the maternal plasma [11-13].  V arious techniques for analyzing fetal DNA in maternal serum 
have been proposed, all with hopes of developing a new method for non-invasive identification 
of fetal aneuploidy. 
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In this project, we investigate next-generation sequencing of maternal plasma DNA as a 
method for non-invasive identification of fetal aneuploidy.  This method has the potential to 
significantly improve sensitivity and specificity over existing prenatal screening methods.  We 
carried out shotgun next-generation sequencing on samples of maternal plasma DNA obtained in 
the first trimester of pregnancies with confirmed aneuploidy and control pregnancies.  T hree 
Trisomy 21 samples were compared to four control samples in order to identify any differences 
in the amount of chromosomal material. 
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2.0  AIMS 
The overall goal of this paper is to demonstrate the identification of fetal aneuploidy by shotgun 
next-generation sequencing of maternal serum.  The data presented and discussed here provides a 
foundation for ongoing research by this group regarding non-invasive prenatal identification of 
fetal aneuploidy by shotgun next-generation sequencing. 
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3.0  BACKGROUND AND SIGNIFICANCE 
3.1 ANEUPLOIDY 
Aneuploidy is a type of chromosome condition in which there is an atypical number of 
chromosomes. [4]  Typically, every cell in the human body has 23 pairs of chromosomes, or a 
total of 46 chromosomes.  The first 22 pairs of chromosomes are numbered 1 through 22 and the 
last are the sex chromosomes, X and Y.  One chromosome from each pair is inherited from our 
mother while the other is inherited from our father, giving the full set of 46 chromosomes.  In the 
case of aneuploidy, there are extra or missing chromosomes in the cells of the body.  Having 
extra or missing chromosomes can have severe effects on the health and function of the human 
body.  Aneuploidy is thought to occur in 20-50% of conceptions, the majority of which are not 
compatible with life [1-3].   
Most cases of aneuploidy are caused by nondi sjunction of chromosomes in meiosis 1. 
When a pair of homologous chromosomes fails to separate and move to opposite poles during 
meiosis, it results in the uneven division of chromosomes between gametes.  I f one of these 
gametes were to be fertilized, it would result in fetal aneuploidy.  Nondisjunction occurs 
spontaneously, but is more likely to occur in a woman’s oocytes as she ages [4, 6].  I t is well 
recognized that the risk to have a pregnancy with aneuploidy increases with maternal age [4-7].   
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3.1.1 Trisomy 
Trisomy, which occurs when there are three copies of a chromosome, is the most common type 
of aneuploidy to result in live births [4].  Although trisomy has been reported in all 
chromosomes, most are lethal in early pregnancy [2, 3].  The most common types of trisomy 
seen in live births are Trisomy 21, Trisomy 18, and Trisomy 13 [4].   
 Trisomy 21, or Down syndrome, occurs when there are 3 copies of chromosome 21, 
rather than the typical 2 copies.  S imilarly, Trisomy 18 occurs when there is an extra copy of 
chromosome 18 a nd Trisomy 13 occurs when there is an extra copy of chromosome 13.  
Individuals with Down syndrome can have mild to moderate mental retardation, certain facial 
characteristics, and health problems, such as heart defects or intestinal problems [4].  Trisomy 18 
and Trisomy 13 are not as common as Down syndrome, but are more severe.  Babies born with 
these conditions have severe mental retardation, serious health problems, and typically do no t 
survive very long after birth [4]. 
 
3.2 PRENATAL DIAGNOSIS OF ANEUPLOIDY 
3.2.1 Non-invasive screening for fetal aneuploidy 
Non-invasive screening tests are routinely done as a way to identify pregnancies at an increased 
risk for fetal aneuploidy, such as Trisomy 21.  A  variety of prenatal screening methods are 
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available throughout pregnancy, including First Trimester Screen, Maternal Serum Screening, 
Integrated Screening, and Ultrasound.   
First Trimester Screening (FTS), which is done between 11 and 13 6/7 weeks of 
pregnancy, helps to identify pregnancies at an increased risk for Trisomy 21 and Trisomy 18 [8].   
This test utilizes a combination of measurements obtained from blood work and ultrasound.  
Firstly, levels of two biochemical markers, called pregnancy-associated plasma protein A 
(PAPP-A) and human chorionic gonadotropin (hCG), are measured in the mother’s blood [8].  
Secondly, a measurement of the nuchal translucency (NT), the fluid filled area behind the fetal 
neck, is obtained by ultrasound [8].  These measurements are combined to adjust a woman’s age-
related-risk to a risk that is more specific to her pregnancy.  It is estimated that the sensitivity of 
FTS is approximately 79-90% with a false positive rate of 5% [8-10].   
Maternal Serum Screening (MSS) is done between 15-20 weeks of pregnancy and can 
help identify pregnancies with an increased risk for Trisomy 21 and Trisomy 18, as well as open 
neural tube defects (ONTDs) [8].  The most commonly practiced type of MSS is the Quad 
Screen, which measures levels of four biochemical markers in the mother’s blood, called 
alphafetoprotein (AFP), human chorionic gonadotropin (hCG), unconjugated estriol (uE3), and 
inhibin-A [8].  This test detects approximately 75-80% of babies with Trisomy 21 [8, 14]. 
Integrated Screening is a screening test that combines information typically obtained for 
FTS and MSS.  The Integrated Screen combines measurements of PAPP-A and NT in the first 
trimester along with measurements of AFP, hCG, uE3, and inhibin A in the second trimester [8].  
The results of this test are not reported until the second trimester, after all of the necessary 
information has been collected and analyzed [8].  Although Integrated Screening takes the 
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longest to complete, it provides the highest sensitivity of all the screening methods, detecting 
approximately 93-96% of pregnancies with Trisomy 21 [15, 16].  
 Ultrasound can also be a useful screening tool for fetal aneuploidy.  Ultrasounds done 
between 18-20 weeks can visualize certain features that are commonly seen in fetuses with 
chromosome conditions, such as heart defects, choroid plexus cysts, and other physical features 
[8, 17].  However, ultrasounds have a low sensitivity and specificity for detecting pregnancies 
with a chromosome condition and are not typically used as the primary screening tool for fetal 
aneuploidy [17, 18]. 
3.2.2 Invasive prenatal diagnosis of fetal aneuploidy. 
Prenatal diagnosis of fetal aneuploidy is done by testing fetal cells, which can be obtained by two 
different procedures: chorionic villus sampling (CVS) or amniocentesis.  These procedures are 
invasive and carry a risk for pregnancy loss, which is estimated to be between 0.1%-1.0% [19-
22].  Thus, prenatal diagnosis is not routinely offered during pregnancy.  Traditionally, women 
are offered prenatal diagnosis if they are 35 years or older at the time of delivery or if they are 
identified as “high risk” based on a screening test. 
CVS is done between 10-13 weeks gestation and can diagnose chromosome conditions 
with about 99.9% accuracy [8].  The procedure, which can be done transcervically or 
transabdominally, involves collecting a sample of the placenta.  The placental cells are grown in 
culture and then analyzed with traditional cytogenetic methods, such as f luorescent in situ 
hybridization (FISH) and karyotyping, to identify any chromosome conditions [8].   
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Like CVS, amniocentesis can diagnose chromosome conditions with about 99.9% 
accuracy.  This test, which is done any time after the 16th week of pregnancy, involves the 
transabdominal collection of a sample of amniotic fluid [8].    The cells in this fluid, called 
amniocytes, are grown in culture and then analyzed with traditional cytogenetic methods to 
identify any numerical or structural changes in the chromosomes. [8] 
3.3 NEW DIRECTION: NON-INVASIVE PRENATAL DIAGNOSIS 
3.3.1 Cell free fetal DNA in maternal plasma. 
Cell free fetal DNA was first discovered in maternal circulation in 1997 [11], creating new and 
exciting possibilities for non-invasive prenatal diagnosis (NIPD).  Studies have estimated that the 
fetal DNA represents approximately 5-10% of the cell free DNA present in maternal plasma [12, 
13]. 
Following the discovery of cell free fetal DNA in maternal circulation, efforts were 
initially focused on detection and measurement of paternally derived fetal DNA, like the Y 
chromosome, because it is easily distinguishable from maternal DNA [23, 24].  Developments in 
this research have begun to take place in clinical practice.  For example, cell free fetal DNA may 
now be analyzed as a non-invasive method for fetal sex determination, a t est often used as a  
screening step for X-linked disorders [23, 24].  Cell free fetal DNA has also been clinically used 
to verify fetal Rhesus D blood group status in Rh negative mothers, which can determine the 
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necessity of Rhogam [25-27].  M ore recently, analysis of cell free fetal DNA has correctly 
diagnosed paternally inherited thalassemia and achondroplasia [28, 29]. 
3.3.2 Proposed methods of NIPD using cell free fetal DNA. 
Since the discovery of cell free fetal DNA in maternal circulation, multiple methods for NIPD of 
fetal aneuploidy have been explored.  The most significant obstacle preventing progress towards 
this goal is the fact that maternally inherited fetal alleles are identical in sequence to their 
endogenous maternal counterparts.  Therefore, recent efforts in the field have focused on the use 
of functional genomic screens to identify potential diagnostic biomarkers on a neuploid 
chromosomes.  This strategy relies on t he observation that the maternal DNA present in the 
plasma mostly originates from maternal leukocytes while fetal DNA in the plasma originates 
from the trophoblast or placenta [30-33].  Studies have identified differences in gene expression 
or DNA methylation patterns between placental cells and maternal leukocytes, which can be 
useful in differentiating between maternal and fetal DNA [34-36].  These unique differences 
between fetal DNA and maternal DNA can be used for selective amplification of heterozygous 
fetal polymorphisms, whose allelic ratios are then quantified for the diagnosis or exclusion of 
aneuploidy [36-38]. 
 Although these methods are promising, they are technologically complex and face 
practical limitations.  Firstly, these methods require independent identification of each potential 
biomarker, which must then be extensively validated.  Secondly, methods requiring allelic ratio 
determination at biallelic loci only work if the fetus is heterozygous for the analyzed SNPs.  
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Also, these approaches may be confounded by potential individual differences in allelic-specific 
DNA methylation of mRNA expression. 
3.3.3 Shotgun next-generation sequencing. 
Shotgun next-generation sequencing has recently been explored as a method for NIPD using cell 
free fetal DNA [39-42].  This method utilizes random sequencing of fetal and maternal DNA 
fragments that freely circulate in maternal plasma.  This “shotgun sequencing” creates sequence 
tags of at least 36 base pairs, each representing a small sequence of cell free DNA fragments.  
More than 10 million sequence tags are produced, which are then computationally aligned to 
their chromosomal origin in the human genome.  Perfectly aligned matching tags are then 
quantified according to their chromosome-specific or region-specific location in the genome.  
This makes it possible to identify small alterations in inter-chromosomal ratios which may be 
due to fetal aneuploidy.  This concept is outlined in Figure 1 [39].  
Unlike other methods of analyzing cell free fetal DNA, shotgun next-generation 
sequencing does not rely on epigenetic differences and does not require pretest identification of 
biomarkers.  The extensive work up that is necessary for other noninvasive methods is not 
required for shotgun next-generation sequencing because this method simply sequences a 
random portion of the cell free DNA in the maternal plasma [39].  Despite the randomness of the 
sequencing, the fraction that is sequenced is quite representative of the overall human genome 
and shotgun next-generation sequencing has been previously shown to be effective and accurate 
at identifying fetal aneuploidy [39-42]. 
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Figure 1:  Schematic illustration of the procedural framework for using massively parallel genomic 
sequencing for the noninvasive prenatal detection of fetal chromosomal aneuploidy.   
Fetal DNA (thick red fragments) circulates in maternal plasma as a minor population among a h igh 
background of maternal DNA (black fragments).  A sample containing a representative profile of DNA 
molecules in maternal plasma is obtained.   One end of each plasma DNA molecule was sequenced for 
a[pproximately 36 bp us ing the Solexa sequencingby-synthesis approach. The chromosomal origin of 
each 36-bp sequence was identified through mapping to the human reference genome by bioinformatics 
analysis.  The number of unique sequences mapped to each chromosome was counted and then expressed 
as a percentage of all unique sequences generated for the sample, termed%chrN for chromosome N.  Z-
scores for each chromosome and each test sample were calculated using the formula shown.  The z-score 
of a potentially aneuploid chromosome is expected to be higher for pregnancies with an aneuploid fetus 
(cases E–H shown in green) than for those with a euploid fetus (cases A–D shown in blue). 
                              Copyright 2008 National Academy of Sciences, U.S.A. [39] 
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4.0  MATERIALS AND METHODS 
4.1 DATA COLLECTION 
4.1.1 Patient population. 
The patient population consists of pregnant women over the age of 18 years who were seen in at 
Magee Women’s Hospital in Pittsburgh, Pennsylvania between 10-13 weeks gestation.  Two 
populations of patients were invited to participate in the research:  1) patients who were 
undergoing CVS or amniocentesis and 2) patients who were undergoing First Trimester 
Screening.  Theoretically, patients who choose to pursue prenatal diagnosis through CVS or 
amniocentesis may do s o because they have an increased risk for aneuploidy.  Therefore, this 
population of patients may represent a “high risk” group and may be more likely to provide our 
laboratory with positive controls.  Alternatively, those undergoing only First Trimester Screen 
may represent a “low risk” group and may be more likely to provide our laboratory with negative 
controls.   
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4.1.2 Participant recruitment and informed consent. 
All participant recruitment and informed consent was obtained in the Center for Medical 
Genetics at Magee Women’s Hospital in Pittsburgh, Pennsylvania under IRB protocol number 
PRO0709003.  Patients were recruited by genetic counselors and genetic counseling interns 
either during a genetic counseling appointment or as a short consult.   
For individuals undergoing genetic counseling, participation in this research was offered 
by the genetic counselor at the end of the appointment.  For individuals having only First 
Trimester Screen and no counseling, participation was offered by a g enetic counseling intern 
(who is employed as a patient recruiter by the laboratory) before the blood draw portion of the 
First Trimester Screen.   
Informed consent involved a discussion of the background and aims of the research 
project as well as participation requirements, participant rights, and sample handling.  After 
discussing the risks and benefits of participation in the research study, participants were given 
ample time to read the consent form (Appendix A), ask questions, and voice concerns.  
Consenting patients provided initials on each page of the consent form as well as a signature, 
printed name, and date on t he last page.  The individual obtaining informed consent also 
provided a signature, printed name, and date on the last page of the consent form.   
A copy of each consent form is kept in the patient’s chart at Magee Women’s Hospital 
while the original copy is filed in a locked cabinet at the research laboratory.  No sample was 
obtained without the consent of a patient. 
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4.1.3 Sample collection and tracking. 
Following informed consent, participants were provided a script for blood work and were taken 
to the phlebotomy lab.  Approximately 36 C C of blood was drawn from each patient, filling 
approximately 6 purple top tubes.  Samples were then transferred to the research laboratory at 
Magee Women’s Research Institute within 2 hours of collection for further processing. 
Documentation of each blood draw and sample transfer to Magee Women’s Research 
Institute for this research was recorded in the patients’ Reference Lab on Magee’s Genetic 
Information System (GIS).  Upon entering the laboratory, all samples are de-identified and given 
a unique bar code, which will be used to track the patient’s blood sample, plasma-derived DNA, 
sequencing library, and the resulting data.  This unique bar code will also be linked to all 
available clinical and demographic information including diagnostic test results and birth 
outcome.   
4.2 SAMPLE PROCESSING 
4.2.1 Separation of plasma from whole blood. 
Whole blood was centrifuged at 1600xg for 13 min at 4°C, setting acceleration and deceleration 
to 3.  1ml aliquots of plasma were pipetted into 1.5ml microcentrifuge tubes and centrifuged at 
16000xg for 10 min at 4°C to pellet cellular debris.  900uL from each tube was pipette into a 
clean 1.5ml microcentrifuge tube.  Plasma aliquots were stored at -80°C. 
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4.2.2 DNA extraction from plasma.  
DNA was extracted from plasma using the QIAamp DNA Multi Kit and supplied reagents.  
Briefly, 1 vial of frozen plasma was thawed to room temperature and divided into two tubes.  
40uL of Qiagen Protease was added to each tube and the sample was mixed by inverting 5 times.  
400uL Buffer AL was added to each tube and the sample was vortexed for 15 sec.  Samples were 
incubated at 56°C for 10 min.  400uL 100% ethanol was added to each tube and the tubes were 
vortexed for 15 sec.  600uL of mixture was applied to the spin column and centrifuged at 6000xg 
for 1 min, repeating this step as many times as necessary to get the entire plasma sample through 
the same column.  The column was washed by adding 500uL Buffer AW and centrifuging for 1 
min at 6000xg.  The column was washed again by adding 500uL Buffer AW2 and centrifuging at 
maximum speed for 4 min.  T o remove residual ethanol, the column was placed in a clean 
collection tube and centrifuged at maximum speed for 2 min.  To elute the DNA, the column was 
placed in a 1.5mL tube and 75uL of RNase/DNase free water was added to the column.  The 
column was incubated at room temperature for 5 minutes and then centrifuged for 1 minute at 
6000xg. 
4.2.3 Real time PCR analysis of SRY and Bglobin. 
Primers and probe sequences for the real time PCR reaction were obtained from Maron, et al.  
SRY:  F orward primer 5’ – TCCTCAAAAGAAACCGTGCAT – 3’;  Reverse primer 5’ – 
AGATTAATGGTTGCTAAGGACTGGAT – 3’;  Probe  5’  – FAM – 
CACCAGCAGTAACTCCCCACAACCTCTTT – TAMRA – 3’.   B-globin:  Forward primer 5’ 
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– GTGCACCTGACTCCTGAGGAGA – 3’;  R everse primer 5’ – 
CCTTGATACCAACCTGCCCAG – 3’;  P robe  5’  – FAM – 
AAGGTGAACGTCCATGAAGTTGGTGG – TAMRA – 3’.  
B-globin is an ubiquitous housekeeping gene and was run concurrently with SRY to 
ensure that DNA was present in each sample, irrespective of fetal gender.  In order to estimate 
DNA concentration in the plasma DNA, standard curve DNA was run simultaneously with the 
plasma DNA.  The standard curve DNA was prepared using commercially available DNA with 
known concentrations.  The range of values for the standard curve was 6.4pg/5uL to 
20,000pg/5uL.  Each real time PCR reaction consisted of: 12.5uL 2x TaqMan Universal PCR 
Master Mix, 1.25uL 10uM forward primer, 1.25uL 10uM reverse primer, and 0.0625uL 100uM 
probe.  10uL plasma DNA, 5uL standards, or 10uL water (to serve as a negative control) were 
added to the appropriate wells.  Each plasma DNA sample and the negative control were run in 
triplicate.  The standard curve DNA was run in duplicate.  The thermal cycling conditions were 
initial denaturation step of 95°C for 10 min, followed by 50 cycles of 95°C for 15 sec and 60°C 
for 1 m in.  T he real time PCR reactions were done using the 7900HT Sequence Detection 
System (Applied Biosystems).   
4.2.4 Plasma sequencing. 
The following oligos 5’ – ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TC*T – 3’ and 
5’ - /5Phos/GAT CGG AAG AGC TCG TAT GCC GTC TTC TGC TTG – 3’ were resuspended 
in TE and annealed in 1X T4 DNA Ligase Reaction Buffer (NEB) by heating at 95°C for 5 
minutes and then slowly cooled to room temperature for a final concentration of 36µM annealed 
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adaptor.  P lasma DNA fragments were end repaired and then terminal A-residues were added 
using the NEBNext End Repair and the NEBNext dA-tailing modules as per manufacturer’s 
protocols (NEB).   Following reaction cleanup using the MinElute Cleanup kit (Qiagen), DNA 
fragments were then combined with 0.05uM adaptor and 400U T4 DNA ligase (NEB) and 
incubated for 1 hou r at 16°C.  After reaction cleanup with MinElute Cleanup kit, PCR was 
performed using the following primers: 5’ – CAA GCA GAA GAC GGC ATA CGA GCT CTT 
CCG ATC*T - 3’ and 5’ – AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC 
CTA CAC GAC G CT CTT CCG ATC*T – 3’ and Phusion High-Fidelity DNA Polymerase 
(NEB).  PCR conditions were an initial denaturation (98°C 30s), 30 cycles of 98°C for 10s, 65°C 
for 30s and 72°C for 30s, with a final extension of 72°C for 7 min.  Following amplification, the 
PCR reaction was cleaned up using the MinElute PCR Purification Kit (Qiagen). 
4.3 DATA ANALYSIS 
4.3.1 Analytical framework  
The data analyzed and discussed in this paper is based on the comparison of three known 
Trisomy 21 cases against four normal samples.  The data was gathered on the Illumina Genome 
Analyzer IIx and was analyzed using the statistical model proposed in a previous publication by 
our lab [40].  The data discussed in this paper was analyzed based on the null hypothesis that the 
amount of genetic material in a given chromosome is equal in the aneuploidy and control 
samples.  This null hypothesis is individually applied to each chromosome.  A p value of less 
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than 0.05 f or a specific chromosome allows us to reject the null hypothesis and accept the 
alternative hypothesis that the amount of genetic material is not equal between the compared 
samples, indicating aneuploidy of that chromosome. 
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5.0  RESULTS 
5.1.1 The Biobank and Sample Statistics. 
Recruiting efforts for this research study are ongoing, with the goal of consenting 1350 
pregnant women who are having CVS or Amniocentesis.  Currently, a total of 592 patients have 
given their consent to participate in this study.  Of those recruited, 183 participants have a 
prenatal diagnostic procedure and 409 had First Trimester Screening only (Table 1).  Therefore, 
our Biobank currently holds 13.5% of our projected total inventory.   
 
Table 1:  Prenatal Testing Pursued by Participants 
Testing Pursued by 
Participants 
Number of 
Participants 
Percentage of 
Participants 
CVS 116 19.59% 
Amniocentesis 67 11.32% 
First Trimester Screen only 409 69.09% 
 
Of the 592 samples collected, there are 16 known cases of aneuploidy (Table 2).  The 
fetal karyotypes of these cases were confirmed by cytogenetic testing following CVS or 
amniocentesis.   
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Table 2:  Known Aneuploidy Cases in Sample Population 
Type of Aneuploidy # of cases 
Monosomy X 
(Turner Syndrome) 
1 
Trisomy 18 
(Edwards syndrome) 
3 
Trisomy 13 
(Patau syndrome) 
1 
Trisomy 14 1 
Trisomy 21 
(Down syndrome) 
10 
 
To ensure that our research produces quality data, it is important that we have an 
adequate collection of aneuploid samples in our Biobank.  Currently, our Biobank contains a 
fraction of the aneuploid samples we anticipated.  In order to increase our inventory of aneuploid 
samples, we hope to improve our recruitment of patients having CVS and amniocentesis.  I n 
theory, patients who elect these procedures may do so because they are at an increased risk to 
have a baby with a chromosome condition.  Thus, the likelihood of collecting an aneuploid 
sample for our study is highest in this population.  
5.1.2 Shotgun sequencing results. 
Shotgun next-generation sequencing was done on three known cases of Trisomy 21 ( samples 
pl96, pl125, and pl134) and four normal samples (pl124, pl132, pl137, and pl161).  The amount 
of chromosomal material in each sample was quantified for chromosomes 1-22.  The value  
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Table 3:  P values of Trisomy 21 samples vs. normal samples at chromosomes 1-22. 
 Trisomy 21 samples vs. Normal samples 
 Sample pl96 versus: Sample pl125 versus: Sample pl134 versus: 
Chromosome pl124 pl132 pl137 pl161 pl124 pl132 pl137 pl161 pl124 pl132 pl137 pl161 
1 1 1 1 1 1 1 1 1 1 1 1 1 
2 1 1 1 1 1 1 1 1 1 1 1 1 
3 1 1 1 1 1 1 1 1 1 1 1 1 
4 1 1 1 1 1 1 1 1 1 1 1 1 
5 1 1 1 1 1 1 1 1 1 1 1 1 
6 1 1 1 0.540655 1 1 1 0.739549 1 1 1 0.141622 
7 1 1 1 1 1 1 1 1 1 1 1 1 
8 1 1 1 1 1 1 1 1 1 1 1 1 
9 0.756034 1 1 1 1 1 1 1 1 1 1 1 
10 1 1 1 1 1 1 1 1 1 1 1 1 
11 1 1 1 0.956444 1 1 1 1 0.296221 0.102155 1 1 
12 1 1 1 1 1 1 1 1 1 1 1 1 
13 1 1 1 1 0.865717 0.180907 1 1 1 1 1 1 
14 1 1 1 1 1 1 1 1 1 1 1 1 
15 1 1 1 1 1 1 1 1 1 1 1 1 
16 1 1 1 1 1 1 1 1 1 1 1 1 
17 1 1 1 1 1 1 1 1 1 1 1 1 
18 1 1 1 1 1 1 1 1 1 0.563806 1 1 
19 1 0.486549 1 1 1 0.929166 1 1 1 1 0.179956 1 
20 1 0.327722 1 1 1 1 1 1 1 1 1 1 
21 1.32E-13 2.93E-14 4.32E-12 3.72E-10 1.95E-14 1.95E-13 0 1.66E-13 1.31E-06 1.56E-05 1.52E-07 4.50E-08 
22 1 1 1 1 0.310996 0.561283 1 1 1 1 1 1 
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obtained for each known Trisomy 21 sample were then compared to the values obtained for all 
four normal samples.  A p value was calculated for each comparison at chromosomes 1-22.  As 
shown in Table 3 (above), the p value for chromosome 21 was statistically significant in each 
example, indicating aneuploidy at this chromosome.  Therefore, shotgun next-generation 
sequencing was able to correctly identify all three cases of Trisomy 21.  These results show that 
this method has great promise as a noninvasive tool for identification of fetal aneuploidy. 
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6.0  DISCUSSION 
6.1 PUBLIC HEALTH IMPLICATIONS 
We demonstrated that shotgun next-generation sequencing of maternal plasma DNA can 
successfully identify Trisomy 21, showing that it is possible to detect fetal aneuploidy using this 
noninvasive method.  This technology could potentially be used as a new method of noninvasive 
screening for fetal aneuploidy, which is likely to have improved accuracy over other screening 
methods.  Development of a scr eening test with greater sensitivity and specificity could have 
significant public health implications.  This would not only provide more accurate identification 
of pregnancies at an increased risk for aneuploidy, but it would also reduce the number of false 
positives.  This in turn would reduce the number of pregnancies that are unnecessarily classified 
as “high risk”, preventing avoidable parental anxiety and reducing the number of pregnancies 
that are put at unnecessary risk of invasive prenatal diagnostic procedures.   
Furthermore, this research lends to world-wide efforts in developing a method for non-
invasive prenatal diagnosis (NIPD) of fetal aneuploidy.  Such a development could potentially 
eliminate the need for CVS and amniocentesis, allowing prenatal diagnosis of aneuploidy 
without the risk for pregnancy loss.  Research groups around the world are racing to develop the 
first clinically applicable method of NIPD.  Although countless methods have been explored, it 
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has been predicted that shotgun next-generation sequencing will become the dominant 
technology for NIPD [23]. 
6.2 FUTURE DIRECTION OF THIS RESEARCH 
6.2.1 Direct extension of this project. 
The data presented and discussed in this paper provides a foundation for ongoing research by this 
group.  As we approach our recruitment goal, we will perform shotgun next-generation 
sequencing on samples of maternal plasma DNA obtained from large cohorts of confirmed 
aneuploidy and control pregnancies.  Following this, our research group will use novel statistical 
analysis to determine the sensitivity and specificity of shotgun next-generation sequencing, 
which will then be compared to the sensitivity and specificity of First Trimester Screen.  Based 
on the data discussed in this paper, we predict that shotgun next-generation sequencing will have 
high predictive powers and will identify fetal aneuploidy with greater accuracy than the First 
Trimester Screen.   
Our research group also hopes to develop user-friendly software for non-invasive 
detection of aneuploidy.  This software will use the data obtained from shotgun next-generation 
analysis as input and will use a graphical user interface implemented in Java.  The final report 
will include test scores and the clinical interpretation of the test scores.  Development of this 
software is an important step in the clinical application of shotgun next-generation sequencing 
for identification of fetal aneuploidy.   
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6.2.2 Future directions. 
Our research group has also developed an interest in using shotgun next-generation sequencing 
as a method for prenatal diagnosis of monogenic diseases.  We have recently begun to invite a 
small population of patients who have a personal or family history of a known or suspected 
genetic condition to participate in pilot study that would investigate this.  Paternal samples may 
be collected along with maternal samples for this study.  Maternal consent for this pilot study is 
included in the same consent form used for the project discussed in this paper (Appendix A).  
Fathers who are consenting have a different consent form, which is not attached to this 
document. 
6.3 CONSIDERATIONS OF NONINVASIVE PRENATAL DIAGNSOIS 
As noninvasive prenatal diagnosis (NIPD) works toward transition from “possible” to “clinically 
applicable”, there are many factors that should be considered.  Such a transition would change 
not only the way prenatal diagnosis is done, but also the way we approach prenatal diagnosis.  
NIPD could provoke drastic changes in the well-established clinical standards of Prenatal Care 
and would undoubtedly have effects on the way genetic counselors provide prenatal genetic 
counseling to these patients.   
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6.3.1 Clinical and Practical considerations. 
Currently, the American Congress of Obstetrics and Gynecology (ACOG) states that all pregnant 
women should be offered First Trimester Screen, regardless of their age.  ACOG also states that 
CVS and amniocentesis should be offered to women who are over the age of 35 or  have an 
increased risk for aneuploidy based on screening results.  It is interesting to consider what 
ACOG would recommend should noninvasive prenatal diagnosis (NIPD) become the new 
standard of fetal aneuploidy diagnosis.  If NIPD reaches its intended potential, it would have all 
the prenatal diagnostic capabilities of traditional cytogenetic methods.  This would completely 
eliminate the need for fetal cells, and would therefore eliminate the need for CVS and 
amniocentesis.  One could then ask whether screening methods, such as First Trimester Screen, 
would be indicated.  I f these screening tests exist to identify who should be offered prenatal 
diagnosis in attempt to reduce the number of pregnancies placed at unnecessary risk for 
miscarriage, one could deduce that this type of screening would not be necessary for NIPD, as 
this procedure would not carry a risk for pregnancy loss.  Therefore, NIPD could not only 
eliminate the need for CVS and amniocentesis, but it could also eliminate the need for 
noninvasive screening tests like the First Trimester Screen.  Because ACOG states that all 
patients should be offered screening, becomes possible that all pregnant women could be offered 
NIPD.  This type of change would undoubtedly have an effect on the way that genetic counselors 
provide prenatal counseling to patients.   
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6.3.2 Implications for Genetic Counseling 
It is not uncommon for First Trimester Screen to be ordered by a  physician with little to no 
pretest counseling.  Only women who are over the age of 35  are routinely offered genetic 
counseling prior to screening, while most others only have counseling if their First Trimester 
Screen is screen positive.  Regardless, genetic counseling is always provided before CVS and 
amniocentesis in order to thoroughly discuss the risks, benefits, and implications of prenatal 
diagnosis and to obtain informed consent.  This process has thus far been effective and 
pragmatic.   
However, a new plan for providing prenatal genetic counseling would be required if 
NIPD becomes clinically applicable.  I f NIPD becomes offered to all pregnant women, it is 
possible that the test could be ordered by a physician with little to no pretest counseling.  Should 
a patient then have a positive result, counseling would only be provided post-test.  Such a 
structure would impose upon a woman’s reproductive rights and raise ethical issues concerning 
autonomy, informed consent, and the “right not to know”. 
Although NIPD does not carry a risk for pregnancy loss, the potential impact of a positive 
result is enough to warrant extensive pretest genetic counseling.  It is essential that the patient be 
properly informed of NIPD and the results it could generate before having this test.  P retest 
counseling should include a discussion about the implications of aneuploidy, whether the patient 
would want to know this information, and what she would do with the information.   
However, if NIPD becomes clinically available to all pregnant women, we could expect 
the uptake of this test to be significant.  Genetic counseling is a relatively small field and many 
areas in the country do not have this service.  Therefore, it may not be practically feasible to 
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provide sufficient pretest genetic counseling to every patient who pursues NIPD.  Thus, the 
issues of “When and how do we counsel these patients?” may quickly become an issue of “Who 
will counsel them?”  This situation would create a greater need for prenatal genetic counselors, 
which may not be financially achievable for some hospitals and clinics.  Consequently, we may 
be faced with a situation in which patients are either briefly counseled by phys icians or not 
counseled at all prior to NIPD of fetal aneuploidy. 
6.4 CONCLUSION 
The data presented in this paper demonstrates that shotgun next-generation sequencing can 
correctly identify Trisomy 21, showing that it is possible to identify fetal aneuploidy using this 
noninvasive method for cell free fetal DNA analysis.  This technique has potential as a  new 
noninvasive screening method for fetal aneuploidy, which is expected to have increased 
sensitivity and sensibility over existing screening methods.  This technique also has potential as a 
method for noninvasive prenatal diagnosis (NIPD).  Should shotgun next-generation sequencing 
of maternal plasma become clinically applicable as a screening or diagnostic test, its 
implementation would have effects on the well-established clinical standards of prenatal care.   
Careful consideration should be given to the potential impact of these noninvasive tests so that 
clinicians, genetic counselors, and other health care professionals can provide the highest 
standard of care possible. 
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APPENDIX  
 
  
CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY 
 
TITLE: Biological Analysis of Fetal Nucleic Acids in Maternal Plasma 
 
Mother’s Consent Form 
 
PRINCIPAL INVESTIGATOR:  David G. Peters, Ph.D. 
      Associate Professor 
 Department of Obstetrics, Gynecology and Reproductive Sciences 
      Magee-Womens Research Institute 
      204 Craft Avenue 
      Pittsburgh, PA 15213 
      Office: 412-641-2979 
      Fax: 412-641-6156 
 
CO-INVESTIGATORS:   W. Allen Hogge, M.D. 
      Professor and Chair 
  Department of Obstetrics, Gynecology and Reproductive Sciences 
      Director, Center for Medical Genetics 
      University of Pittsburgh/Magee-Womens Hospital 
      300 Halket Street 
      Pittsburgh, PA 15213 
      Tel: 412-641-4212  
 
University of Pittsburgh  
SCHOOL OF MEDICINE 
Department of Obstetrics, Gynecology and Reproductive Sciences 
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      Aleksander Rajkovic, M.D. 
      Associate Professor 
  Department of Obstetrics, Gynecology and Reproductive Sciences 
      University of Pittsburgh/Magee-Womens Hospital 
      300 Halket Street 
      Pittsburgh, PA 15213 
      Tel: 412-641-4164  
 
      Marta Kolthoff, M.D. 
      Assistant Professor  
  Department of Obstetrics, Gynecology and Reproductive Sciences 
      University of Pittsburgh/Magee-Womens Hospital 
      300 Halket Street 
      Pittsburgh, PA 15213 
      Tel: 412-641-4168 
 
      Hyagriv Simhan, M.D. 
  Associate Professor  
  Department of Obstetrics, Gynecology and Reproductive Sciences 
      University of Pittsburgh/Magee-Womens Hospital 
      300 Halket Street 
      Pittsburgh, PA 15213       
      412-641-4222 
   
      Stephen P Emery M.D. 
      Assistant Professor  
  Department of Obstetrics, Gynecology and Reproductive Sciences 
      University of Pittsburgh/Magee-Womens Hospital 
      300 Halket Street 
      Pittsburgh, PA 15213 
      Tel: 412-641-3382 
 
 
SOURCE OF SUPPORT:   Department of Obstetrics, Gynecology and Reproductive Sciences 
 
 
Why is this research being done? 
 
It is currently very difficult to test for diseases and abnormalities during pregnancy. Two common medical procedures 
that are used to test the health of the unborn baby are chorionic villus sampling (CVS) and amniocentesis. Both of 
these procedures carry a level of risk to the baby.   
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The study in which you are being asked to participate will explore new minimal risk methods for testing the health of 
unborn babies. These new methods use only a routine blood sample taken from the mother’s arm. This blood sample 
is obtained in exactly the same way as any other routine blood sample. We will investigate whether blood samples 
obtained in this way can be used to evaluate the genetic disorders of unborn babies. 
 
Who is being asked to take part in this research study? 
 
We are inviting 1350 pregnant women (>18 years old) who are undergoing either chorionic villus sampling or 
amniocentesis to participate in this research.  Also included in this study are women who are undergoing a first 
trimester blood test for fetal chromosomal abnormalities. We are also recruiting a small number (50) of partners of 
the above women so that paternal samples may also be collected in cases where a genetic anomaly in the family 
tree is known or suspected. 
 
What procedures will be performed for research purposes? 
 
Screening Procedures: 
None 
 
Experimental Procedures: 
 
If you decide to take part in this research study, we will obtain a blood sample (about 8 teaspoonfuls) from a vein in 
your arm. This will require only a few minutes of your time. In addition, if you are having chorionic villus sampling or 
amniocentesis, we will save the cells that would normally be discarded afterwards and these will be analyzed in the 
same way as your blood sample in order to compare the results.  If you are not undergoing chorionic villus sampling 
or CVS we may save a very small portion of your placenta or some blood from the umbilical cord. These are tissues 
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that would otherwise be discarded after birth. This testing will allow the investigators to confirm that their analysis 
from your blood is a correct one.  Approximately one month after your due date we may review your medical records 
to obtain general information about the pregnancy outcome. 
 
The samples we obtain from you may be stored for an indefinite period of time prior to experimental analysis.  If this 
is the case the sample will be stored in a freezer in the Principal Investigator’s laboratory.  This laboratory is in a 
security controlled building.  Identifiers that link your sample to your medical records will be removed and your 
sample will be encoded such that only the Principal Investigator will know the details of the code.  The details of the 
code will remain in a locked filing cabinet in the Principal Investigator’s office, which itself is kept locked and is within 
a security controlled building. 
  
No information obtained in this study will directly benefit you or your unborn child. Therefore, the results of the testing 
will not be communicated to study participants. 
 
Monitoring/Follow-up Procedures: 
None 
 
What are the possible risks, side effects, and discomforts of this research study? 
 
The risks of this procedure are no greater than those you would experience when undergoing a routine blood test.  
You may experience pain/discomfort from the needle insertion; slight bruising at the site, and there is a slight risk of 
infection and a very rare possibility of fainting. Because we will obtain information from your medical records there is 
a slight risk of breach of confidentiality. We will guard against this by removing any information that could be used to 
identify you and replacing this with a code. The only people with access to this code will be the principal investigator 
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(Dr Peters) and co-investigators (Drs Emery, Hogge, Kolthoff, Rajkovic and Simhan). The details of the code will be 
kept in a locked filing cabinet in the principal investigators office, which is in a restricted access building. 
 
Although we will not directly be performing paternity tests, it is possible that we will identify rare instances where the 
mother and father have genotypes that are not consistent with the genotype of the baby. This would indicate non-
paternity. In these instances the results will remain confidential and will not be shared with the study participants. 
 
What are possible benefits from taking part in this study? 
 
You will receive no direct benefit from taking part in this research study.  However, information learned from this 
study may contribute to better tests in the future to detect disorders of unborn babies. 
 
What treatments or procedures are available if I decide not to take part in this research study? 
 
The clinical treatments or procedures you undergo will not be altered in any way if you decide not to take part in this 
research study. 
 
If I agree to take part in this research study, will I be told of any new risks that may be found during the 
course of the study? 
 
You will be promptly notified if, during the conduct of this research study, any new information develops which may 
cause you to change your mind about continuing to participate. 
 
Will my insurance provider or I be charged for the costs of any procedures performed as part of this 
research study? 
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Neither you, nor your insurance provider, will be charged for the costs of any of the procedures performed for the 
purpose of this research study (i.e., the Screening Procedures, Experimental Procedures, or Monitoring/Follow-up 
Procedures described above). You will be charged, in the standard manner, for any procedures performed for your 
routine medical care. 
 
Will I be paid if I take part in this research study? 
 
There is no financial compensation associated with participation in this study. 
 
Who will pay if I am injured as a result of taking part in this study? 
 
University of Pittsburgh researchers and their associates who provide services at University of Pittsburgh Medical 
Center (UPMC) recognize the importance of your voluntary participation in their research studies. These individuals 
and their staffs will make reasonable efforts to minimize, control, and treat any injuries that may arise as a result of 
this research. If you believe that you are injured as a result of the research procedures being performed, please 
contact immediately the Principal Investigator or one of the co-investigators listed on the first page of this form. 
 
Emergency medical treatment for injuries solely and directly related to your participation in this research study will be 
provided to you by the hospitals of UPMC. It is possible that UPMC may bill your insurance provider for the costs of 
this emergency treatment, but none of these costs will be charged directly to you. If your research-related injury 
requires medical care beyond this emergency treatment, you will be responsible for the costs of this follow-up care 
unless otherwise specifically stated below. There is no plan for monetary compensation. You do not, however, waive 
any legal rights by signing this form. 
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Who will know about my participation in this research study? 
 
Any information about you obtained from this research will be kept as confidential (private) as possible. All records 
related to your involvement in this research study will be stored in a locked file cabinet. Your identity on these records 
will be indicated by a case number rather than by your name, and the information linking these case numbers with 
your identity will be kept separate from the research records. You will not be identified by name in any publication of 
the research results. 
 
Will this research study involve the use or disclosure of my identifiable medical information? 
 
This research study will involve the recording of current and/or future identifiable medical information from your 
hospital and/or other (e.g., physician office) records. The information that will be recorded will be limited to 
information concerning the outcome of your pregnancy.  
 
Note: Research outcomes from this study will not be stored in your medical records. 
 
Who will have access to identifiable information related to my participation in this research study? 
 
In addition to the investigators listed on the first page of this authorization (consent) form and their research staff, the 
following individuals will or may have access to identifiable information (which may include your identifiable medical 
information) related to your participation in this research study:  
 
Authorized representatives of the University of Pittsburgh Research Conduct and Compliance Office may 
review your identifiable research information (which may include your identifiable medical information) for 
the purpose of monitoring the appropriate conduct of this research study.  
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In unusual cases, the investigators may be required to release identifiable information (which may include 
your identifiable medical information) related to your participation in this research study in response to an 
order from a court of law. If the investigators learn that you or someone with whom you are involved is in 
serious danger or potential harm, they will need to inform, as required by Pennsylvania law, the appropriate 
agencies. 
 
Authorized representatives of the UPMC hospitals or other affiliated health care providers may have access 
to identifiable information (which may include your identifiable medical information) related to your 
participation in this research study for the purpose of (1) fulfilling orders, made by the investigators, for 
hospital and health care services (e.g., laboratory tests, diagnostic procedures) associated with research 
study participation; (2) addressing correct payment for tests and procedures ordered by the investigators; 
and/or (3) for internal hospital operations (i.e. quality assurance). 
 
 
For how long will the investigators be permitted to use and disclose identifiable information related to my 
participation in this research study? 
 
The investigators may continue to use and disclose, for the purposes described above, identifiable information (which 
may include your identifiable medical information) related to your participation in this research study for a minimum of 
seven years after final reporting or publication of a project.  
 
May I have access to my medical information that results from my participation in this research study? 
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In accordance with the UPMC Notices of Privacy Practices document that you have been provided, you are permitted 
access to information (including information resulting from your participation in this research study) contained within 
your medical records filed with your health care provider. 
 
Is my participation in this research study voluntary? 
 
Your participation in this research study, to include the use and disclosure of your identifiable information for the 
purposes described above, is completely voluntary. (Note, however, that if you do not provide your consent for the 
use and disclosure of your identifiable information for the purposes described above, you will not be allowed to 
participate in the research study.) Whether or not you provide your consent for participation in this research study will 
have no effect on your current or future relationship with the University of Pittsburgh. Whether or not you provide your 
consent for participation in this research study will have no effect on your current or future medical care at a UPMC 
hospital or affiliated health care provider or your current or future relationship with a health care insurance provider. 
 
Your doctor (either Dr Emery, Hogge, Kolthoff, Rajovic or Simhan) is involved as a co-investigator in this research 
study. As both your doctor and a research investigator, s/he is interested both in your medical care and the conduct 
of this research study. Before agreeing to participate in this research study, or at any time during your study 
participation, you may discuss your care with another doctor who is not associated with this research study. You are 
not under any obligation to participate in any research study offered by your doctor. 
 
May I withdraw, at a future date, my consent for participation in this research study? 
 
You may withdraw, at any time, your consent for participation in this research study, to include the use and disclosure 
of your identifiable information for the purposes described above. Note, however, that if you withdraw your consent 
for the use and disclosure of your identifiable medical record information for the purposes described above, you will 
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also be withdrawn, in general, from further participation in this research study. Any identifiable research or medical 
information recorded for, or resulting from, your participation in this research study prior to the date that you formally 
withdrew your consent may continue to be used and disclosed by the investigators for the purposes described above.  
Should you withdraw your blood sample and chorionic villus/amniocentesis sample will be destroyed. 
 
To formally withdraw your consent for participation in this research study you should provide a written and dated 
notice of this decision to the principal investigator of this research study at the address listed on the first page of this 
form. 
 
Your decision to withdraw your consent for participation in this research study will have no effect on your current or 
future relationship with the University of Pittsburgh. Your decision to withdraw your consent for participation in this 
research study will have no effect on your current or future medical care at a UPMC hospital or affiliated health care 
provider or your current or future relationship with a health care insurance provider. 
 
If I agree to take part in this research study, can I be removed from the study without my consent? 
It is possible but highly unlikely that you may be removed from the research study by the researchers. 
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************************************************************************ 
VOLUNTARY CONSENT 
 
The above information has been explained to me and all of my current questions have been answered. I understand 
that I am encouraged to ask questions about any aspect of this research study during the course of this study, and 
that such future questions will be answered by a qualified individual or by the investigator(s) listed on the first page of 
this consent document at the telephone number(s) given. I understand that I may always request that my questions, 
concerns or complaints be addressed by a listed investigator.   
 
I understand that I may contact the Human Subjects Protection Advocate of the IRB Office, University of Pittsburgh 
(1-866-212-2668) to discuss problems, concerns, and questions; obtain information; offer input; or discuss situations 
in the event that the research team is unavailable.   
 
By signing this form, I agree to participate in this research study. A copy of this consent form will be given to me. 
 
 
________________________________________________________ 
Participant’s Signature    
 
 
_______________________________________________________  ___________ 
Printed Name of Participant      Date 
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CERTIFICATION of INFORMED CONSENT 
 
I certify that I have explained the nature and purpose of this research study to the above-named individual(s), and I 
have discussed the potential benefits and possible risks of study participation. Any questions the individual(s) have 
about this study have been answered, and we will always be available to address future questions as they arise.” I 
further certify that no research component of this protocol was begun until after this consent form was signed 
 
 
___________________________________  ________________________ 
Printed Name of Person Obtaining Consent  Role in Research Study 
 
 
_________________________________  ____________ 
Signature of Person Obtaining Consent  Date  
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